Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ticarcillin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 3/20 | 0.98 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.61 |
| ▸ | RECQL | P46063 | 4/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.61 |
| ▸ | POLB | P06746 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | HPGD | P15428 | 2/20 | 0.61 |
| ▸ | TEK | Q02763 | 1/20 | 0.61 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 4/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | RARB | P10826 | 1/20 | 0.59 |
| ▸ | RARG | P13631 | 1/20 | 0.59 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.59 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.59 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.59 |
| ▸ | HRH1 | P35367 | 1/20 | 0.53 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ticarcillin SCHEMBL27742456 | 1.00 | PTGS1 (0.98) | PTGS1SMN1; SMN2KDM4ERECQLTDP1 | |
| Ticarcillin SCHEMBL4228859 | 1.00 | PTGS1 (0.98) | PTGS1SMN1; SMN2KDM4ERECQLTDP1 | |
| Ticarcillin SCHEMBL193733 | 1.00 | PTGS1 (0.98) | PTGS1SMN1; SMN2KDM4ERECQLTDP1 | |
| Ticarcillin SCHEMBL5047437 | 0.99 | PTGS1 (1.00) | PTGS1SMN1; SMN2KDM4ERECQLTDP1 | |
| Ticarcillin SCHEMBL34025 | 0.99 | PTGS1 (1.00) | PTGS1SMN1; SMN2KDM4ERECQLTDP1 | |
| Ticarcillin SCHEMBL10738099 | 0.99 | PTGS1 (1.00) | PTGS1SMN1; SMN2KDM4ERECQLTDP1 | |
| Ticarcillin SCHEMBL10738085 | 0.99 | PTGS1 (1.00) | PTGS1SMN1; SMN2KDM4ERECQLTDP1 | |
| Ticarcillin SCHEMBL28757995 | 0.98 | PTGS1 (0.98) | PTGS1SMN1; SMN2KDM4ERECQLTDP1 | |
| Ticarcillin SCHEMBL9929365 | 0.98 | PTGS1 (0.98) | PTGS1SMN1; SMN2KDM4ERECQLTDP1 | |
| Ticarcillin SCHEMBL4935408 | 0.98 | PTGS1 (0.98) | PTGS1SMN1; SMN2KDM4ERECQLTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117384259-A | Cell penetrating peptides based on influenza virus M2 proteins | 中国医学科学院基础医学研究所 | 2024-01-12 | — | — | CN | claimed |
| CN-112912386-B | Cell penetrating peptides based on influenza virus M2 proteins | 中国医学科学院基础医学研究所 | 2023-10-20 | — | — | CN | claimed |
| US-20020004595-A1 | Process for preparing potassium clavulanate | SMITHKLINE BEECHAM CORPORATION | 2002-01-10 | — | — | US | claimed |
| EP-0918520-A4 | PROCESS FOR PREPARING POTASSIUM CLAVULANATE | SMITHKLINE BEECHAM CORP (US) | 2000-01-12 | — | — | EP | claimed |
| EP-0918520-A1 | PROCESS FOR PREPARING POTASSIUM CLAVULANATE | SMITHKLINE BEECHAM CORPORATION (US) | 1999-06-02 | — | — | EP | claimed |
| WO-1997047301-A1 | IMPROVED PROCESS FOR PREPARING POTASSIUM CLAVULANATE | SMITHKLINE BEECHAM CORPORATION (US) | 1997-12-18 | — | — | WO | claimed |
| CN-119789870-A | Multicomponent pharmaceutical compositions and kits containing nitric oxide releasing compounds and methods of use thereof | 诺欧生物有限责任公司 | 2025-04-08 | — | — | CN | disclosed |
| CN-113861268-B | Cell penetrating peptides and methods of making and using the same | 恩特拉达治疗学股份有限公司 | 2025-04-01 | — | — | CN | disclosed |
| CN-119136833-A | Membrane translocation domain and uses thereof | 俄亥俄州创新基金会 | 2024-12-13 | — | — | CN | disclosed |
| CN-117384259-A | Cell penetrating peptides based on influenza virus M2 proteins | 中国医学科学院基础医学研究所 | 2024-01-12 | — | — | CN | disclosed |
| CN-117242080-A | Boron-containing pyrazole compounds, compositions comprising the same, methods and uses thereof | 勃林格殷格翰动物保健美国公司 | 2023-12-15 | — | — | CN | disclosed |
| CN-112912386-B | Cell penetrating peptides based on influenza virus M2 proteins | 中国医学科学院基础医学研究所 | 2023-10-20 | — | — | CN | disclosed |
| CN-116547409-A | Pulsed plasma enhanced chemical vapor deposition method and system | SIO2医药产品公司 | 2023-08-04 | — | — | CN | disclosed |
| US-20060122282-A1 | METHOD FOR TREATING SKIN DISORDERS WITH XANTHOPHYLLS | NU-TEIN CO., INC. | 2006-06-08 | — | — | US | disclosed |
| US-5750684-A | BACTERICIDES | BEECHAM GROUP PLC. (GB) | 1998-05-12 | — | — | US | disclosed |
| EP-0112049-B1 | PROCESS FOR THE PREPARATION OF BETA-LACTAM COMPOUNDS | BEECHAM GROUP PLC (GB) | 1987-09-09 | — | — | EP | disclosed |
| EP-0112049-A1 | Process for the preparation of beta-lactam compounds | BEECHAM GROUP PLC (GB) | 1984-06-27 | — | — | EP | disclosed |
| US-4385060-A | BACTERICIDES AND PROPHYLAXIS | BEECHAM GROUP LIMITED (GB) | 1983-05-24 | — | — | US | disclosed |
| EP-0026644-B1 | ORTHO-TOLYL ESTER OF AN ALPHA-CARBOXY PENICILLIN, PROCESS FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE PENICILLIN | BEECHAM GROUP PLC (GB) | 1982-12-01 | — | — | EP | disclosed |
| EP-0026644-A1 | Ortho-tolyl ester of an alpha-carboxy penicillin, process for its preparation and pharmaceutical compositions comprising the penicillin | BEECHAM GROUP PLC (GB) | 1981-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020004595-A1 | Process for preparing potassium clavulanate | PROC, KCNQ5, KCNK5 | PTGS1 2807/4885SMN1; SMN2 4056/4885KDM4E 1867/4885 |
| US-20060122282-A1 | METHOD FOR TREATING SKIN DISORDERS WITH XANTHOPHYLLS | COL1A1, COL2A1, KRT18 | PTGS1 908/4885SMN1; SMN2 4229/4885KDM4E 2315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.